Skip to main content

The association of baseline N-terminal pro-B-type natriuretic peptide with short and long-term prognosis following percutaneous coronary intervention in non-ST segment elevation acute coronary syndrome with multivessel coronary artery disease: a retrospective cohort study



Several studies have shown that N-terminal pro-B-type natriuretic peptide (NT-proBNP) is strongly correlated with the complexity of coronary artery disease and the prognosis of patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS), However, it remains unclear about the prognostic value of NT-proBNP in patients with NSTE-ACS and multivessel coronary artery disease (MCAD) undergoing percutaneous coronary intervention (PCI). Therefore, this study aimed to reveal the relationship between NT-proBNP levels and the prognosis for NSTE-ACS patients with MCAD undergoing successful PCI.


This study enrolled 1022 consecutive NSTE-ACS patients with MCAD from January 2010 to December 2014. The information of NT-proBNP levels was available from these patients. The primary outcome was in-hospital all-cause death. In addition, the 3-year follow-up all-cause death was also ascertained.


A total of 12 (1.2%) deaths were reported during hospitalization. The 4th quartile group of NT-proBNP (> 1287 pg/ml) showed the highest in-hospital all-cause death rate (4.3%) (P < 0.001). Besides, logistic analyses revealed that the increasing NT-proBNP level was robustly associated with an increased risk of in-hospital all-cause death (adjusted odds ratio (OR): 2.86, 95% confidence interval (CI) = 1.16–7.03, P = 0.022). NT-proBNP was able to predict the in-hospital all-cause death (area under the curve (AUC) = 0.888, 95% CI = 0.834–0.941, P < 0.001; cutoff: 1568 pg/ml). Moreover, as revealed by cumulative event analyses, a higher NT-proBNP level was significantly related to a higher long-term all-cause death rate compared with a lower NT-proBNP level (P < 0.0001).


The increasing NT-proBNP level is significantly associated with the increased risks of in-hospital and long-term all-cause deaths among NSTE-ACS patients with MCAD undergoing PCI. Typically, NT-proBN P > 1568 pg/ml is related to the all-cause and in-hospital deaths.

Peer Review reports


Individuals with multivessel coronary artery disease (MCAD) account for approximately 40–70% of all non-ST segment elevation acute coronary syndrome (NSTE-ACS) patients who undergo coronary angiography [1,2,3]. Currently, percutaneous coronary intervention (PCI) has been considered as an option for the treatment of MCAD and left main (LM) disease, which is ascribed to its higher procedural success rates and comparable benefits [4,5,6,7]. However, the incidence rates of cardiovascular morbidity and mortality after PCI remain high in this population [8, 9]. Thus, it is important to develop a prognostic biomarker to identify the high-risk patients.

Several studies have shown that the plasma levels of natriuretic peptides, such as B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), are robustly related to the prognosis for NSTE-ACS patients [10,11,12]. Furthermore, previous studies have demonstrated that the increased NT-proBNP levels among NSTE-ACS patients are independently associated with the presence of more complex and severe coronary lesions [13,14,15]. However, it remains unclear about the prognostic value of NT-proBNP in patients with NSTE-ACS and MCAD undergoing PCI. This study aimed to investigate the relationship between NT-proBNP levels and the short-term prognosis for NSTE-ACS patients with MCAD.


Study design

More details about the cohort were presented in our previous research [16], which was designed to detect the association between parenteral anticoagulation therapy and the clinical outcomes of NSTE-ACS patients undergoing PCI. In brief, altogether 8197 NSTE-ACS patients undergoing PCI were enrolled from 5 centers from January 1st, 2010 to December 31st, 2014. Specifically, the patient inclusion criteria were as follows, patients aged 18 years or older who were diagnosed with MCAD, those whose NT-proBNP levels were determined on the first day of admission, and those with cardiac arrest and return of circulation. MCAD was defined as lesions with ≥ 50% diameter stenosis in the LM artery or ≥ 2 major coronary vessels with ≥ 50% stenosis. The patient exclusion criteria were shown below: the pregnant patients or those with missing baseline NT-proBNP levels were excluded from this study. The enrolled patients were divided into 4 groups based on the quartiles of NT-proBNP level. Ultrasonic cardiography was performed after admission, and the left ventricular ejection fraction (LVEF) was calculated by Simpson's biplane method. The estimated glomerular filtration rate (eGFR) was calculated by the Modification of Diet in Renal Disease equation among the Chinese patients [17]. Our study protocol was approved by the Central Ethics Committee of Guangdong Provincial People’s Hospital (Guangzhou, China). This study was conducted in accordance with the Declaration of Helsinki.

Data collection

Data were obtained from the first interview when the patients were admitted to the hospital. Baseline characteristic data, including demographic data and medical history, were recorded by the responsible nurse or doctor. The procedural information was obtained from the catheterization report. The laboratory examinations for all patients were carried out during the first 24 h after admission before the procedure was performed, and the NT-proBNP levels were measured by the electrochemiluminescence immunoassay (Roche Diagnostics, Germany). All patients received the drug eluting stent. All interventional strategies were selected at the discretion of the heart team. In-hospital and follow-up assessments were performed by means of clinic visits or telephone interviews from November 7th, 2015 to December 30st, 2016.


The primary outcome was in-hospital all-cause death. The secondary outcomes were all-cause death during the 3-year follow-up and in-hospital major adverse cardiovascular events (MACE), which were defined as a composite of all-cause death, myocardial infarction (MI) and stroke. The definitions of all clinical complications assessed during the follow-up period were the same as the original registry [16]. Death was defined as all-cause death, regardless of the cardiac or non-cardiac origin, according to death records. According to the third version of Universal Definition of Myocardial Infarction, MI was defined as classical symptoms accompanied by the elevation of cardiac injury biomarker. Stroke was defined as the presence of a new focal neurologic deficit of vascular origin, with signs or symptoms lasting for over 24 h. The clinical events committee evaluated all clinical outcomes independently.

Statistical analysis

Statistical analysis was implemented using SAS version 9.4 (SAS Institute, Cary, NC, USA). Continuous variables were presented as mean ± standard deviation (SD) and compared by Student’s t-test (parametric variables). Categorical variables were expressed as absolute and relative frequencies. The predictive value of NT-proBNP for different clinical outcomes was evaluated by multivariate regression analyses, and it was included as a continuous variable after logarithmic transformation. All the confounders included in the final model were the clinical important factors or were significant in univariate analyses. The log NT-proBNP, Anaemia, Chronic heart failure, Chronic kidney disease, NSTEMI, LVEF and age were incorporated into the final model for death analysis; whereas log NT-proBNP, Anaemia, Chronic heart failure, chronic kidney disease, NSTEMI, LVEF, age, Diabetes, Myocardial infarction and operation time were incorporated into the final model for MACE analysis. Moreover, receiver-operating characteristic (ROC) curves were plotted to assess the ability of NT-proBNP in discriminating surviving patients from those who died during hospitalization. Also, the Youden index was utilized to determine the best cutoff of NT-proBNP level in predicting all-cause death, and this level was expected to be used in further analyses. Further, cumulative event analyses were performed to compare the long-term prognosis between patients divided by the best cutoff level of NT-proBNP. All P-values < 0.05 were considered statistically significant.


Baseline characteristics

Among the 1022 patients who met the final inclusion and exclusion criteria, 118 (11.5%) were female, with the average age of 65.8 (standard difference: 10.5; range, 33–90) years. All the enrolled patients were of Han nationality. There were 585 patients older than 65 years in total. Variables were compared by baseline NT-proBNP quartile values. The baseline characteristics are presented in Table 1. It was observed that, patients with high NT-proBNP levels were older, with lower body weight (BW), higher heart rates, as well as more frequent non-ST segment elevation myocardial infarction (NSTEMI), chronic kidney disease (CKD), anaemia diabetes and stroke than those with low NT-proBNP levels. In addition, chronic heart failure, prior MI, prior PCI and lower LVEF were more frequent in the higher NT-proBNP quartiles. Furthermore, most of the treatment variables did not show significant differences among the different NT-proBNP groups, except for the operation time.

Table 1 Baseline characteristics of different baseline NT-proBNP levels

In-hospital outcomes

Altogether 12 (1.2%) in-hospital all-cause deaths were reported. Typically, patients with NT-proBNP > 1287 pg/ml had the highest all-cause death rate (4.3% highest vs. 0.0% lowest, P < 0.001, Table 2). Patients in the highest quartile of NT-proBNP had the highest in-hospital MACE rate (6.3% highest vs 0.8% lowest, P < 0.001), but there was no significant difference in in-hospital stroke or MI between different groups (Table 2). The higher NT-

Table 2 Clinical outcomes of different baseline NT-proBNP levels

proBNP level was associated with a higher risk of in-hospital all-cause death (univariate: odd ratio (OR): 3.06, 95% confidence interval (CI): 1.77–5.28, P < 0.001; multivariate: adjusted OR: 2.86, 95% CI: 1.16–7.03, P = 0.022) (Table 3). Additionally, the increasing NT-proBNP level was related to an increased risk of in-hospital MACE (adjusted OR: 2.09, 95% CI: 1.35–3.23, P = 0.001) after adjusting for confounders. Additionally, according to discrimination analyses, NT-proBNP was adequate for predicting the in-hospital all-cause death (Fig. 1). The area under the ROC curve (AUC) was 0.888 (95% CI: 0.834–0.941, P < 0.001). The best cutoff level of NT-proBNP in predicting in-hospital death was 1568 pg/ml (sensitivity: 91.7%, specificity: 78.5%).

Table 3 Univariate and multivariate analyses of in-hospital outcomes
Fig. 1

ROC analysis of NT-proBNP in predicting in-hospital all-cause death; AUC: area under the curve; CI: confidence interval

Long-term outcomes

All the 1022 patients were followed up for 3 years. Deaths were recorded in 121 (11.8%) patients. Thereafter, the long-term all-cause death was compared between patients with baseline NT-proBNP ≤ 1568 pg/ml and those with baseline NT-proBNP > 1568 pg/ml. As a result, patients with higher NT-proBNP levels showed a significantly higher long-term event rate than those with lower NT-proBNP levels (P < 0.0001) (Fig. 2).

Fig. 2

Cumulative event analysis during follow-up between patients with high and low levels of NT-pro BNP (cutoff: 1568 pg/ml)


This study discovered that patients with NT-proBNP levels > 1287 pg/ml showed the highest in-hospital all-cause death and MACE rates. In addition, this study determined the optimal cutoff of 1568 pg/ml to evaluate in-hospital death. During the 3-year follow-up period, patients with higher NT-proBNP levels (> 1568 pg/ml) had a higher all-cause death rate.

Findings in this study showed that the increased NT-proBNP level was related to the adverse outcomes of NSTE-ACS patients with MCAD. However, the pathophysiological mechanism underlying the association between ischaemia and NT-proBNP elevation remains unknown yet. It has been reported in previous studies that, myocardial ischaemia can cause transient and permanent increase in wall stress, myocardial tension, and subsequently induce BNP neurohormone release from the ventricular myocardium [18,19,20]. Furthermore, several studies [20,21,22] have revealed the up-regulation of ventricular BNP genes upon myocardial hypoxia, thus provoking an increase in the plasma NT-proBNP level. In addition, the NT-proBNP level is strongly related to cardiac function, which can be used to detect left ventricular (LV) systolic and diastolic dysfunction [23, 24]. An immediate increase in plasma BNP level may occur after myocardial ischaemia [9, 25] and before the elevation of traditional markers for myocardial necrosis. Meanwhile, the increase magnitude of BNP level is proportional to the severity of myocardial ischaemia [26]. In this study, patients with NT-proBNP levels greater than 1287 pg/ml presented with the highest LV dysfunction level (mean LVEF, 49.85 ± 14.66). Therefore, it was speculated that the higher NT-proBNP level on admission was the combined result of both myocardial ischaemia before the index event and the index event itself. Another mechanism underlying the NT-proBNP elevation among patients with acute coronary syndromes (ACS) was the permanently elevated NT-proBNP level that reflected ventricular dysfunction or heart failure before the index event. Interestingly, patients in NT-proBNP > 1287 pg/ml group had near-normal LVEF (49.85% ± 14.66%), so it was surmised that these patients experienced a certain form of diastolic dysfunction, since previous study found that NT-proBNP plasma levels increased in patients with diastolic dysfunction [27].

Laurenz Jaberg et al. demonstrated that the plasma NT-proBNP level was a strong predictor for outcome in patients undergoing acute LM coronary artery stenting. However, this was a retrospective study, and the NT-proBNP level was measured only in 71 ACS patients with LM disease upon hospital admission [11]. Our study extended this interaction to patients with NSTE-ACS and MCAD, another population at high risk of ischemia. MCAD predisposes to a more severe and extensive myocardial ischaemia, which results in the higher NT-proBNP level.

Cardiovascular diseases are associated with several endocrine situations, like diabetes, hypothyroidism and so on [28, 29]. In this study, the highest quartile of NT-proBNP which had the highest mortality and MACE also had the highest proportion of diabetes. Generally, diabetes is regarded as a risk factor of cardiovascular evens, and several mechanisms, including ubiquitin proteasome system, adiponectin, carbonic anhydrase, has been established to clarify the relationship between diabetes and the initiation and progression of atherosclerosis, restenosis after PCI and myocardial remolding [28, 30,31,32].

NT-proBNP is positively associated with age [33]. In this research, the group with a higher level of NT-proBNP also had an older age. Age, together with gender, are two important factors that influence the disease distribution and outcomes, [34, 35]which may affect our results.

To remove the influence of confounders like diabetes and age, multivariate regression analyses were carried out and the result is the same both before and after the adjustment. As for gender, there is no significant difference between these four groups.

Nevertheless, NT-proBNP was still robustly associated with death after adjusting for LVEF in this study. Previous studies have demonstrated that the association between NT-proBNP and death is not linked to LVEF [36, 37]. Furthermore, the NT-proBNP level is previously found to be associated not only with myocardial ischaemia in coronary heart disease (CHD), but also with all kinds of cardiac pathological conditions, such as activation of the renin–angiotensin–aldosterone system [38]. Besides, tissue hypoxia is found in previous studies to induce the release of BNP in the absence of LV dysfunction [39]. In this population, patients with higher NT-proBNP levels upon admission have a greater extent of myocardial ischaemia because of the more severe coronary lesions and subclinical LV dysfunction, possibly consequent to the effects of chronic repetitive ischaemia on the myocardium [40, 41]. All these mechanisms may result in poor prognosis and an increased risk of death. However, more investigations are warranted to further study the exact mechanism underlying the connection between NT-proBNP and death. However, the casual relationship between the NT-proBNP and CV death cannot be confirmed due to the study design, and further basic researches were warranted to demonstrated the potential mechanism.


Some limitations should be noted in this study. Firstly, although great efforts were made, we were still unable to adjust for all the potential confounders due to the retrospective study design. The impact of treatment changes over time was not determined as well. Secondly, the exact cause of death was not determined due to an unavailability of first-hand clinical documents, making it difficult for us to determine the causal relationship between death and the increasing NT-proBNP. Thirdly, due to the lack of persistent monitoring of in-hospital NT-proBNP, this study was unable to determine a relationship between changes in NT-proBNP level and prognosis. Therefore, more detailed studies are warranted.


Findings in this study suggest that, a high level of NT-proBNP on admission is associated with a higher risk of in-hospital all-cause death among NSTE-ACS patients with MCAD undergoing PCI. Moreover, NT-proBNP > 1568 pg/ml is a reasonable cutoff value related to the in-hospital and long-term all-cause deaths.

Availability of data and materials

The datasets used and/or analysed during the current study available from the corresponding author on reasonable request.



B-type natriuretic peptide


Estimated glomerular filtration


Left main


Left ventricular


Left ventricular ejection fraction


Major adverse cardiovascular events


Multivessel coronary artery disease


N-terminal pro-B-type natriuretic peptide


Non-ST segment elevation acute coronary syndrome


Percutaneous coronary intervention


Receiver-operating characteristic


  1. 1.

    Montalescot G, Cayla G, Collet J-P, Elhadad S, Beygui F, Le Breton H, et al. Immediate vs delayed intervention for acute coronary syndromes. JAMA. 2009;302 (9):947.

    CAS  PubMed  Article  Google Scholar 

  2. 2.

    Christian W. Hamm Chairperson Germany J-PBC-CF. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.The Task Force for the management of acute coronary syndromes (ACS) in patients presenting with out persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:2999–3054.

    Article  Google Scholar 

  3. 3.

    Windecker SKPAF. ESC Guidelines on myocardial revascularization The Task Forceon Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.

    PubMed  Article  Google Scholar 

  4. 4.

    Kaiser GC, Davis KB, Fisher LD, Myers WO, Foster ED, Passamani ER, et al. Survival following coronary artery bypass grafting in patients with severe angina pectoris (CASS). An observational study. J Thorac Cardiovasc Surg. 1985;89 (4):513–24.

    CAS  PubMed  Article  Google Scholar 

  5. 5.

    Yusuf S, Zucker D, Peduzzi P, Fisher LD, Takaro T, Kennedy JW, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet. 1994;344 (8922):563–70.

    CAS  PubMed  Article  Google Scholar 

  6. 6.

    Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374 (16):1511–20.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Al-Hijji M, El SA, Holmes DR. Revascularization for left main and multivessel coronary artery disease: current status and future prospects after the EXCEL and NOBLE trials. Korean Circ J. 2018;48 (6):447–62.

    PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Arakawa N, Nakamura M, Aoki H, Hiramori K. Relationship between plasma level of brain natriuretic peptide and myocardial infarct size. Cardiology. 1994;85 (5):334–40.

    CAS  PubMed  Article  Google Scholar 

  9. 9.

    Staub D, Nusbaumer C, Zellweger MJ, Jonas N, Wild D, Pfisterer ME, et al. Use of B-type natriuretic peptide in the detection of myocardial ischemia. Am Heart J. 2006;151 (6):1223–30.

    CAS  PubMed  Article  Google Scholar 

  10. 10.

    Lindahl B, Lindback J, Jernberg T, Johnston N, Stridsberg M, Venge P, et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol. 2005;45 (4):533–41.

    CAS  PubMed  Article  Google Scholar 

  11. 11.

    Jaberg L, Toggweiler S, Puck M, Frank M, Rufibach K, Luscher TF, et al. Prognostic value of N-terminal pro-B-type natriuretic peptide in patients with acute coronary syndromes undergoing left main percutaneous coronary intervention. Circ J. 2011;75 (11):2648–53.

    CAS  PubMed  Article  Google Scholar 

  12. 12.

    Toggweiler S, Borst O, Enseleit F, Hermann M, Ruschitzka F, Luscher TF, et al. NT-proBNP provides incremental prognostic information in cardiac outpatients with and without echocardiographic findings. Clin Cardiol. 2011;34 (3):183–8.

    PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Sadanandan S, Cannon CP, Chekuri K, Murphy SA, Dibattiste PM, Morrow DA, et al. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;44 (3):564–8.

    CAS  PubMed  Article  Google Scholar 

  14. 14.

    Palazzuoli A, Gennari L, Calabria P, Quatrini I, Vecchiato L, De Paola V, et al. Relation of plasma brain natriuretic peptide levels in non-ST-elevation coronary disease and preserved systolic function to number of narrowed coronary arteries. Am J Cardiol. 2005;96 (12):1705–10.

    CAS  PubMed  Article  Google Scholar 

  15. 15.

    Navarro EJL, Rubinstein F, Bahit MC, Rolandi F, Perez DAD, Gabay JM, et al. NT-probrain natriuretic peptide predicts complexity and severity of the coronary lesions in patients with non-ST-elevation acute coronary syndromes. Am Heart J. 2006;151 (5):1093.e1-7.

    Article  CAS  Google Scholar 

  16. 16.

    Chen JY, He PC, Liu YH, Wei XB, Jiang L, Guo W, et al. Association of parenteral anticoagulation therapy with outcomes in chinese patients undergoing percutaneous coronary intervention for non-st-segment elevation acute coronary syndrome. JAMA Intern Med. 2019;179 (2):186–94.

    PubMed  Article  Google Scholar 

  17. 17.

    Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, et al. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006;17 (10):2937–44.

    PubMed  Article  Google Scholar 

  18. 18.

    Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339 (5):321–8.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Windhausen F, Hirsch A, Sanders GT, Cornel J, Fischer J, van Straalen JP, et al. N-terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Am Heart J. 2007;153 (4):485–92.

    CAS  PubMed  Article  Google Scholar 

  20. 20.

    Camici PG, Prasad SK, Rimoldi OE. Stunning, hibernation, and assessment of myocardial viability. Circulation. 2008;117 (1):103–14.

    PubMed  Article  Google Scholar 

  21. 21.

    Wiese S, Breyer T, Dragu A, Wakili R, Burkard T, Schmidt-Schweda S, et al. Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and diastolic fiber length. Circulation. 2000;102 (25):3074–9.

    CAS  PubMed  Article  Google Scholar 

  22. 22.

    Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, et al. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J. 2003;17 (9):1105–7.

    CAS  PubMed  Article  Google Scholar 

  23. 23.

    Bibbins-Domingo K, Gupta R, Na B, Wu AH, Schiller NB, Whooley MA. N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007;297 (2):169–76.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Troughton RW, Richards AM. B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. JACC Cardiovasc Imaging. 2009;2 (2):216–25.

    PubMed  Article  Google Scholar 

  25. 25.

    Bassan R, Potsch A, Maisel A, Tura B, Villacorta H, Nogueira MV, et al. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. Eur Heart J. 2005;26 (3):234–40.

    CAS  PubMed  Article  Google Scholar 

  26. 26.

    Sabatine MS, Morrow DA, de Lemos JA, Omland T, Desai MY, Tanasijevic M, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. 2004;44 (10):1988–95.

    CAS  PubMed  Article  Google Scholar 

  27. 27.

    Tschope C, Kasner M, Westermann D, Gaub R, Poller WC, Schultheiss HP. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J. 2005;26 (21):2277–84.

    PubMed  Article  CAS  Google Scholar 

  28. 28.

    Marfella R, Di Filippo C, Siniscalchi M, Sasso FC, Ferraraccio F, et al. The possible role of the ubiquitin proteasome system in the development of atherosclerosis in diabetes. Cardiovasc Diabetol. 2007;6:35.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  29. 29.

    Marfella R, Ferraraccio F, Rizzo MR, Portoghese M, Barbieri M, Basilio C, et al. Innate immune activity in plaque of patients with untreated and L-thyroxine-treated subclinical hypothyroidism. J Clin Endocrinol Metab. 2011;96 (4):1015–20.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  30. 30.

    Torella D, Ellison GM, Torella M, Vicinanza C, Aquila I, Iaconetti C, et al. Carbonic anhydrase activation is associated with worsened pathological remodeling in human ischemic diabetic cardiomyopathy. J Am Heart Assoc. 2014;3 (2):e000434.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  31. 31.

    Sasso FC, Pafundi PC, Marfella R, Calabro P, Piscione F, Furbatto F, et al. Adiponectin and insulin resistance are related to restenosis and overall new PCI in subjects with normal glucose tolerance: the prospective AIRE Study. Cardiovasc Diabetol. 2019;18 (1):24.

    PubMed  PubMed Central  Article  Google Scholar 

  32. 32.

    Marfella R, Sasso FC, Siniscalchi M, Paolisso P, Rizzo MR, Ferraro F, et al. Peri-procedural tight glycemic control during early percutaneous coronary intervention is associated with a lower rate of in-stent restenosis in patients with acute ST-elevation myocardial infarction. J Clin Endocrinol Metab. 2012;97 (8):2862–71.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  33. 33.

    Hill SA, Booth RA, Santaguida PL, Don-Wauchope A, Brown JA, Oremus M, et al. Use of BNP and NT-proBNP for the diagnosis of heart failure in the emergency department: a systematic review of the evidence. Heart Fail Rev. 2014;19 (4):421–38.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Corrao S, Santalucia P, Argano C, Djade CD, Barone E, Tettamanti M, et al. Gender-differences in disease distribution and outcome in hospitalized elderly: data from the REPOSI study. Eur J Intern Med. 2014;25 (7):617–23.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Marcucci M, Franchi C, Nobili A, Mannucci PM, Ardoino I, Investigators R. Defining aging phenotypes and related outcomes: clues to recognize frailty in hospitalized older patients. J Gerontol A Biol Sci Med Sci. 2017;72 (3):395–402.

    PubMed  Google Scholar 

  36. 36.

    de Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, McCabe CH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345 (14):1014–21.

    PubMed  Article  Google Scholar 

  37. 37.

    Ndrepepa G, Braun S, Niemoller K, Mehilli J, von Beckerath N, von Beckerath O, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in patients with chronic stable angina. Circulation. 2005;112 (14):2102–7.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Zhao XY, Li JX, Tang XF, Xu JJ, Song Y, Jiang L, et al. Prognostic value of NT-proBNP in stable coronary artery disease in chinese patients after percutaneous coronary intervention in the drug-eluting stent era. Biomed Environ Sci. 2018;31 (12):859–66.

    PubMed  Google Scholar 

  39. 39.

    Toth M, Vuorinen KH, Vuolteenaho O, Hassinen IE, Uusimaa PA, Leppaluoto J, et al. Hypoxia stimulates release of ANP and BNP from perfused rat ventricular myocardium. Am J Physiol. 1994;266 (4 Pt 2):H1572–80.

    CAS  PubMed  Google Scholar 

  40. 40.

    Casals G, Ros J, Sionis A, Davidson MM, Morales-Ruiz M, Jimenez W. Hypoxia induces B-type natriuretic peptide release in cell lines derived from human cardiomyocytes. Am J Physiol Heart Circ Physiol. 2009;297 (2):H550–5.

    CAS  PubMed  Article  Google Scholar 

  41. 41.

    Caselli C, Prontera C, Liga R, De Graaf MA, Gaemperli O, Lorenzoni V, et al. Effect of Coronary Atherosclerosis and Myocardial Ischemia on Plasma Levels of High-Sensitivity Troponin T and NT-proBNP in Patients With Stable Angina. Arterioscler Thromb Vasc Biol. 2016;36 (4):757–64.

    CAS  PubMed  Article  Google Scholar 

Download references


Not applicable.


This study was supported by grants from Outstanding Young Talent Program of Guangdong Provincial People’s Hospital (KJ012019084), the Science and Technology Planning Project of Guangzhou City (201707010002) and from the China Youth Research Funding (2017-CCA-VG-02). The funders had no role in the design of the study, the data collection and analysis, the decision to publish, or the preparation of the manuscript. The work was not funded by any industry sponsors.

Author information




HW, JL and CY: Methodology, Project administration, CP and DC: Formal analysis and Software, FH, ZL, GW, JL and WX: Data curation, Resources, HW, CP and LY: Writing- Original draft preparation. LJ, LW and GZ: Visualization, Investigation. CJ and TN: Supervision, Validation, HP: Conceptualization, Funding acquisition and Writing- Reviewing and Editing. All authors have read and approved the manuscript. This manuscript has not been published or presented elsewhere in part or in entirety and is not under consideration by another journal.

Corresponding author

Correspondence to Peng-cheng He.

Ethics declarations

Ethics approval and consent to participate

The study protocol was approved by the central ethics committee of the Guangdong General Hospital, Guangzhou, China. [No. GDREC201610H (R1)] The requirement for informed consent was waived because it is a retrospective observational study and patient records and information were anonymized and de-identified prior to analysis.

Consent for publication

This manuscript does not include any individual person’s data.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

He, Wf., Jiang, L., Chen, Yy. et al. The association of baseline N-terminal pro-B-type natriuretic peptide with short and long-term prognosis following percutaneous coronary intervention in non-ST segment elevation acute coronary syndrome with multivessel coronary artery disease: a retrospective cohort study. BMC Cardiovasc Disord 21, 202 (2021).

Download citation


  • N-terminal pro-B-type natriuretic peptide
  • Non-ST segment elevation acute coronary syndrome
  • Multivessel coronary artery disease